¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lymphangioma, any site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acquired progressive lymphangioma
    ÈÄõÁøÇาÇÁ°üÁ¾
  • capillary lymphangioma
    ¸ð¼¼°ü¸²ÇÁ°üÁ¾
  • cystic lymphangioma
    ³¶¼º¸²ÇÁ°üÁ¾
  • cavernous lymphangioma
    ÇØ¸é¸²ÇÁ°üÁ¾
  • lymphangioma
    ¸²ÇÁ°üÁ¾
  • lymphangioma circumscriptum
    ±¹ÇѸ²ÇÁ°üÁ¾
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphangioma
    ¸²ÇÁ°üÁ¾
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acquired progressive lymphangioma
    ÈÄõÁøÇาÇÁ°üÁ¾
  • capillary lymphangioma
    ¸ð¼¼¸²ÇÁ°üÁ¾
  • cavernous lymphangioma
    ÇØ¸é¸²ÇÁ°üÁ¾
  • lymphangioma
    ¸²ÇÁ°üÁ¾
  • lymphangioma circumscriptum
    ±¹ÇѸ²ÇÁ°üÁ¾
  • absorption site
    Èí¼öºÎÀ§
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • definitive site
    Âø»óºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acquired progressive lymphangioma
    ÈÄõ¼º ÁøÇ༺ ¸²ÇÁ°üÁ¾
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • fundic site
    ÀڱùٴÚÀÓ½Å
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cystic lymphangioma<³ª> lymphangioma cysticum
    ³¶¼º¸²ÇÁ°üÁ¾(¡­°üÁ¾).
  • acquired progressive lymphangioma
    ÈÄõ¼º ÁøÇ༺ ¸²ÇÁ°üÁ¾
  • capillary lymphangioma
    ¸ð¼¼ ¸²ÇÁ°üÁ¾ (¡­Î·ðþ)
  • cavernous lymphangioma
    ÇØ¸é(»ó)¸²ÇÁ°üÁ¾
  • cavernous lymphangioma
    ÇØ¸é¾ç ¸²ÇÁ°üÁ¾
  • fluid tumor =lymphangioma
    ¸²ÇÁ°üÁ¾.
  • laryngeal lymphangioma
    ÈĵÎÀӯİüÁ¾
  • lymphangiectodes ; lymphangioma circumscriptum
    ±¹ÇѼº(ÏÑùÚàõ) ¸²ÇÁ°üÁ¾ .
  • lymphangioma
    ¸²ÇÁ°üÁ¾
  • lymphangioma
    ¸²ÇÁ°üÁ¾(¡­Î·ðþ)
  • lymphangioma cavernosum ³ª
    ÇØ¸é¼º(ú­Øúàõ) ¸²ÇÁ°üÁ¾.
  • lymphangioma cavernosum ³ª
    ÇØ¸é¼º(ú­Øúàõ) ¸²ÇÁ°üÁ¾
  • lymphangioma circumscriptum congenitale ³ª
    ¼±Ãµ¼º(à»ô¸àõ) ±¹ÇѼº ¸²ÇÁ°ü Á¾.
  • lymphangioma circumscriptum ³ª
    ±¹ÇѼº(ÏÑùÚàõ) ¸²ÇÁ°üÁ¾.
  • lymphangioma circumscriptum ³ª
    ±¹ÇѼº(ÏÑùÚàõ) ¸²ÇÁ°üÁ¾
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • acceptor site
    ¼ö¿ëºÎÀ§ (â¥é»Ý»êÈ)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • amino acid attachement site
    ¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
  • aminoacyl site
    ¾Æ¹Ì³ë¾Æ½Ç ÀÚ¸®
  • aminoacyl-tRNA site
    ¾Æ¹Ì³ë¾Æ½ÇtRNA ÀÚ¸®
  • antibody combining site
    Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • AP site
    AP ÀÚ¸®
  • A-site
    AÀÚ¸®
  • attachment site
    ºÎÂø(ݾó·)ÀÚ¸®
  • binding site
    °áÇÕ(Ì¿ùê)ÀÚ¸®
  • catalytic site
    Ã˸Å(õºØÚ)ÀÚ¸®
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cystic lymphangioma
    ³¶¼º¸²ÇÁ°üÁ¾
  • lymphangioma
    ¸²ÇÁ°üÁ¾
  • site
    À§Ä¡,»çÀÌÆ®
  • web site
    À¥½ÎÀÌÆ®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
NYHA New York Heart Association
  Heart Disease¿¡ ´ëÇÑ Functional Classification
 &nbs...
ADT Accepted Dental Therapeutics; adenosine triphosphate; admission, discharge, transfer; agar-gel diffu...
AQ achievement quotient; any quantity; aphasia quotient
AWP airway pressure; any willing provider; average of the wholesale prices; average wholesale price
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Site 1 site
5' SS 5' splice site
DBP D site binding protein
ESI Exit-site infection
ESAG expression site-associated gene
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • D18.1
    Lymphangioma, any site
    ¸ðµç ºÎÀ§ÀÇ ¸²ÇÁ°üÁ¾
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • any age
    ¸ðµç ³ªÀÌ
  • capillary lymphangioma
    ¸ð¼¼ ¸²ÇÁ°üÁ¾
  • cavernous lymphangioma
    ÇØ¸é»ó ¸²ÇÁ°üÁ¾
    ¸²ÇÁ°üÀ¸·Î µÇ¾î ÀÖ´Â ÇØ¸é»ó Ç÷°üÁ¾¿¡ ÇØ´çÇÏ´Â °ÍÀ¸·Î À¯¾Æ¿¡¼­ ÀÚÁÖ º¸´Âµ¥, Èä¼âÀ¯µ¹±Ù µÚ¿¡ Å« Á¾±«¸¦ ¸¸µé¸ç Á÷°æÀÌ 15cm¿¡ À̸¦ Á¤µµ±îÁö µÇ¸ç µû¶ó¼­ ¿ÏÀü ÀýÁ¦°¡ ¾î·Á¿î °æ¿ì°¡ Á¾Á¾ Àִµ¥ ÀÌ·± °ÍÀ» ³¶¼º ¸²ÇÁ°üÁ¾À̶ó ÇÑ´Ù.
  • circumscribed lymphangioma
    ±¹ÇѼº ¸²ÇÁ°üÁ¾
  • cystic lymphangioma
    ³¶¼º ¸²ÇÁ°üÁ¾
  • lymphangioma
    ¸²ÇÁ°üÁ¾, ÀӯİüÁ¾
    1. »õ·Î Çü¼ºµÈ ¸²ÇÁ°­ ¹× °ü°­À¸·Î ±¸¼ºµÈ Á¾¾ç. 2. Á¾¾çÀ̶ó±â º¸´Ù´Â ¼±Ãµ¼º º´¼ÒÀÌ´Ù. Ãâ»ý ½Ã ȤÀº ½Ê´ë ÀÌÀü¿¡ ¹ß»ýÇÏ¸ç ¼±Ãµ¼º Ç÷°üÁ¾°ú´Â ´Þ¸® ÀúÀý·Î »ç¶óÁöÁö ¾Ê´Â´Ù. 3. ¸²ÇÁ°üÀÇ °ú¿ÀÁ¾¼º ¶Ç´Â Á¾¾ç¼º Áõ½Ä¿¡ ÀÇÇÔ. ³¶ ¶Ç´Â ÇØ¸é ¸ð¾çÀ» ÃëÇϸç, ÁÖ·Î ÇǺγª °æºÎ, ¾à¿ÍºÎ, Á¾°Ýµ¿, Èĺ¹¸·ÀÇ ½ÉºÎ ¿¬ºÎ Á¶Á÷¿¡ Àß »ý±ä´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¾ç¼ºÀ̳ª ¸²ÇÁ¾×ÀÌ Â÷°Å³ª ÀÖ´ø °ø°£µéÀÌ ºÐÁöÇÏ¿© Å©±â°¡ Ä¿Áö´Â °æ¿ì ÁÖÀ§ ÁÖ¿ä Àå±â¸¦ ¾Ð¹ÚÇϸé ÀÓ»óÀûÀ¸·Î ½É°¢ÇÑ Çö»ó±îÁö ÃÊ·¡ÇÒ ¼ö ÀÖ´Ù.
  • lymphangioma circumscriptum cysticum
    ±¹ÇÑ ³¶Æ÷¼º ÀӯİüÁ¾
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
  • electrophilic site
    Ä£ÀüÀÚ ¹ÝÀÀ¹°
  • molecular site
    ºÐÀÚ À§
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
lymphangioma <oncology, tumour> A localised collection of lymphatic vessels resulting in a nodule or mass. most are congenital.
(27 Sep 1997)
lymphangioma capillare varicosum A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lymphangioma cavernosum A condition of conspicuous dilation of lymphatic vessels in a fairly circumscribed region, frequently with the formation of cavities or "lakes" filled with lymph.
Synonym: cavernous lymphangiectasis.
(05 Mar 2000)
lymphangioma circumscriptum A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lymphangioma, cystic A lymphangioma, often very large, usually occurring in the neck area, and composed of large, multilocular thin-walled cysts. It is also called hygroma or cystic hygroma.
(12 Dec 1998)
lymphangioma cysticum A condition characterised by a fairly well circumscribed group of several or numerous, cystlike, dilated vessels or spaces lined with endothelium and filled with lymph.
Synonym: cystic lymphangiectasis.
(05 Mar 2000)
lymphangioma simplex A circumscribed region or focus of several to numerous lymphatic vessels that are moderately dilated.
Synonym: simple lymphangiectasis.
(05 Mar 2000)
lymphangioma superficium simplex A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lymphangioma tuberosum multiplex A cutaneous lesion characterised by multiple, slightly red, cystlike nodules (located chiefly on the trunk), resulting from fairly large lymphatic vessels and spaces, and groups of proliferating endothelial cells; the lesion has some gross resemblance to spiradenoma, except for the characteristic location.
(05 Mar 2000)
lymphangioma xanthelasmoideum A capillary lymphangioma with colloid degeneration of the elastic tissues of the skin, characterised by yellow-brown or gray-brown plaques that may be only slightly raised above the surface of the skin.
(05 Mar 2000)
acceptor site The ribosomal binding site for the aminoacyl-tRNA during protein synthesis.
(05 Mar 2000)
acceptor splicing site Boundary between the right end of an intron and the left end of the adjacent exon.
Synonym: acceptor splicing site.
(05 Mar 2000)
active site <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site).
(06 May 1997)
allosteric site A specific site on a multi-subunit enzyme or other protein that is not the substrate binding site, but that when reversibly bound by an effector, induces a conformational change in the protein, altering its catalytic or binding properties.
(12 Dec 1998)
amidation site <molecular biology> A C terminus consensus sequence, required for C terminus amidation of peptides. Consensus is glycine, followed by 2 basic amino acids (arg or lys).
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • any
    ¾î¶²
  • any number of
    ²Ï ¸¹Àº
  • any time
    ¾ðÁ¦µçÁö
  • at any rate
    ÇÏ¿©Æ°
  • at any time
    ¾ðÁ¦¶óµµ
  • any
    ¹«¾ùÀ̳ª;´©±¸µç;¾ó¸¶µçÁö;´©±º°¡;¾Æ¹«°Íµµ;¾Æ¹«µµ;Á¶±Ýµµ;¾ó¸¶°£Àº Á¶±ÝÀº;Á¶±ÝÀ̶óµµ(~longer ÀÌÁ¦ ÀÌ ÀÌ»óÀº)
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
  • ceru(s)site
    ¹é¿¬±¤
  • county seat (site)
    ±ºÃ» ¼ÒÀçÁö;±ºÀÇÇàÁ¤ Áß½ÉÁö
  • launching site
    ¹ß»ç±âÁö
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
  • site
    À§Ä¡;Àå¼Ò;¿ëÁö;ºÎÁö !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á